Carna turns MD Anderson leukemia pact into a binding trial contract, and will pay for it
Carna Biosciences will supply monzosertib and bear study costs in a Phase 1b trial at MD Anderson for relapsed or refractory AML, now under a signed contract; the notice reports no patient entry or results, and Carna will not routinely announce registry updates.